Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay (Q24337937)

Stephen Chan

7

0 references

Emad A. Rakha

Emad A Rakha

6

0 references

Andrew Green

Andrew R Green

9

0 references

Ian Ellis

Ian O Ellis

8

0 references

author name string

Fabrício F T Barros

1

0 references

Tarek M A Abdel-Fatah

2

0 references

Christopher C Nolan

4

0 references

Alice C Durham

Breast Cancer Research and Treatment

5

0 references

language of work or name

English

0 references

publication date

April 2014

0 references

published in

0 references

volume

144

0 references

issue

2

0 references

page(s)

273-85

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s10549-014-2871-4

0 references

cites work

Individualization of breast cancer based on histopathological features and molecular alterations

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Receptor tyrosine kinase signalling as a target for cancer intervention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Prognostic markers in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Bright-field microscopy visualization of proteins and protein complexes by in situ proximity ligation with peroxidase detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

HER2/neu: mechanisms of dimerization/oligomerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

Proximity ligation: a specific and versatile tool for the proteomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

7 January 2021

Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

7 January 2021

The Nottingham prognostic index in primary breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

7 January 2021

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

7 January 2021

Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

7 January 2021

X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2871-4

7 January 2021